Stromal Antigen Targeting by a Humanised Monoclonal Antibody: An Early Phase II Trial of Sibrotuzumab in Patients with Metastatic Colorectal Cancer

@article{Hofheinz2003StromalAT,
  title={Stromal Antigen Targeting by a Humanised Monoclonal Antibody: An Early Phase II Trial of Sibrotuzumab in Patients with Metastatic Colorectal Cancer},
  author={R Hofheinz and Salah-Eddin Al-Batran and Frank Hartmann and Gernot Hartung and Dirk J{\"a}ger and Christoph Renner and Paul Tanswell and Ulrich Kunz and Andree Amelsberg and Hartmut Kuthan and Gregor Stehle},
  journal={Oncology Research and Treatment},
  year={2003},
  volume={26},
  pages={44 - 48}
}
Background: A novel immunological approach to colon cancer therapy is the antibody targeting of the fibroblast activation protein (FAP), which is highly expressed by stroma cells of this tumour. Unconjugated sibrotuzumab (BIBH 1), which is a humanised version of the murine anti-FAP mAb F19, was investigated for its anti-tumour activity, safety and pharmacokinetics. Patients and Methods: Patients with metastatic colorectal cancer received weekly intravenous infusions of unconjugated sibrotuzumab… 

Figures and Tables from this paper

Phase II trial of single agent Val-boroPro (talabostat) inhibiting fibroblast activation protein in patients with metastatic colorectal cancer

This phase II trial of Val-boroPro demonstrated minimal clinical activity in patients with previously treated metastatic colorectal cancer, however it provides the initial proof-of-concept that physiologic inhibition of FAP activity can be accomplished in Patients with colore CT cancer, and lays the groundwork for future studies targeting the tumor stroma.

Effective Immunoconjugate Therapy in Cancer Models Targeting a Serine Protease of Tumor Fibroblasts

It is shown that mAb FAP5-DM1 combines excellent efficacy and tolerability and provides a first assessment of the mode of action of a novel drug candidate for tumor stroma targeting, thus encouraging further development toward clinical testing of this treatment paradigm.

Radioimmunotherapy of Fibroblast Activation Protein Positive Tumors by Rapidly Internalizing Antibodies

The results show the potential of ESC11 and ESC14 as potent radioimmunoconjugates or antibody–drug conjugates for diagnostic and therapeutic use in patients with FAP-expressing tumors.

Population Pharmacokinetics of Sibrotuzumab, A Novel Therapeutic Monoclonal Antibody, in Cancer Patients

A robust population pharmacokinetic model was developed and evaluated for sibrotuzumab, which identified a possible need to consider body weight when designing dosage regimen for future clinical cancer trials.

Therapeutic Antibodies and Immunologic Conjugates

  • N. Cheung
  • Biology
    Abeloff's Clinical Oncology
  • 2020

Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells

The data support performing a phase I clinical trial in which MPM patients are treated with adoptively transferred FAP-specific re-directed T cells, which showed antigen-specific functionality in vitro and in vivo.

Genomics and emerging biomarkers for immunotherapy of colorectal cancer.

Rationale Behind Targeting Fibroblast Activation Protein–Expressing Carcinoma-Associated Fibroblasts as a Novel Chemotherapeutic Strategy

This work is taking advantage of FAP's restricted expression and unique substrate preferences to develop a FAP-activated prodrug to target the activation of a cytotoxic compound within the tumor stroma.

Human monoclonal antibodies targeting carbonic anhydrase IX for the molecular imaging of hypoxic regions in solid tumours

A complementary pattern of tumour regions targeted in vivo by the clinical-stage vascular-targeting antibody L19 and the anti-CA IX antibody A3 is observed, indicating that a homogenous pattern of in vivo tumour targeting could be achieved by a combination of the two antibodies.
...

References

SHOWING 1-10 OF 17 REFERENCES

A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer.

  • A. ScottG. Wiseman L. Old
  • Medicine, Biology
    Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2003
Repeat infusions of the humanized anti-FAP antibody sibrotuzumab can be administered safely to patients with advanced FAP-positive cancer, and a maximum tolerated dose was not reached.

Antibody targeting in metastatic colon cancer: a phase I study of monoclonal antibody F19 against a cell-surface protein of reactive tumor stromal fibroblasts.

  • S. WeltC. Divgi L. Old
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1994
The FAP tumor fibroblast antigen is highly expressed in primary and metastatic colorectal carcinomas and shows limited expression in normal adult tissues and is suggested for possible diagnostic and therapeutic applications of humanized mAbF19 and m AbF19 constructs with novel immune and nonimmune effector functions.

Population pharmacokinetics of antifibroblast activation protein monoclonal antibody F19 in cancer patients.

The pharmacokinetics of antistromal mAbF19 were well defined in these two studies with different solid tumour types, and were comparable with those of other murine monoclonal antibodies that do not bind to normal tissue antigens or blood cells.

Radiolabeled anti-CD33 monoclonal antibody M195 for myeloid leukemias.

In an effort to avoid nonspecific cytotoxicity associated with 131I in future trials for minimal residual disease, short-range, alpha particle-emitting radioisotopes are conjugated to HuM195 using a bifunctional chelate, 2-(p-isothiocyanatobenzyl)-cyclohexyldiethyl-enetriaminep entaacetic acid, with high efficiency and specific activities.

Antibodies in the therapy of colon cancer.

Genetically engineered antibody constructs provide an exciting approach to address and subsequently overcome some of the problems identified for unmodified IgG, and should increase the dose fraction localized in tumors versus normal tissue and thereby improve the delivery capacity.

Monoclonal antibody therapy for solid tumors.

Basic theories behind antibody development and their clinical implementation as treatment for solid tumors are reviewed and common solid tumors, including breast, colon and lung cancers are reviewed.

Therapy of patients with human T-cell lymphotrophic virus I-induced adult T-cell leukemia with anti-Tac, a monoclonal antibody to the receptor for interleukin-2.

The use of a MoAb that prevents the interaction of IL-2 with its receptor on ATL cells provides a rational approach for the treatment of this malignancy.

Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers.

The results suggest that the F19+ phenotype correlates with specialized fibroblast functions in wound healing and malignant tumor growth, and may serve as a target for antibodies labeled with radioisotopes or toxic agents, or inflammatogenic antibodies, in carcinoma patients.

Antitumor effects of L6, an IgG2a antibody that reacts with most human carcinomas.

Mouse monoclonal antibody L6 (IgG2a subtype) recognizes a ganglioside antigen expressed at the surface of cells from human non-small-cell lung carcinomas, breast carcinomas, and colon carcinomas. We